Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX Debt Repayment
Cash used to repay borrowings during the period.
Boston Scientific CorporationNYSE: BSX
Debt Repayment · Q2 FY2026 · quarter ended Jun 2026
Debt repayment turns positive
Q2 FY2026 debt repayment was $1.66B, compared with -$314M a year earlier. Trailing-twelve-month debt repayment was $979M. Over 3 fiscal years it compounded at +43.8% a year.
Context
- Debt repayment amounted to 2.4% of revenue in FY2025, down 8.5 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly debt repayment holds near $1.66B or moves back toward the trailing-twelve-month quarterly average of $244.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (491M) USD
- Year-over-year change
- -126.9%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (491M) | -126.9% |
| FY2024 | 2024-12-31 | 1.83B | +45775.0% |
| FY2023 | 2023-12-31 | (4M) | +97.6% |
| FY2022 | 2022-12-31 | (165M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Debt Repayment vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's LTM Jun 2026 debt repayment of $979M is the largest of the 11 companies compared; the peer median is $474.5K.
- Its year-over-year change of +579.9% is the 2nd highest of 10, against a peer median of -2.2%.
- Debt repayment amounts to 4.7% of revenue for BSX, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $979M | +579.9% | +43.8% | 4.7% | |
| LTM Jun 2026 | $912.41M | +410.9% | — | 35.1% | |
| LTM Sep 2026 | $160.05M | -27.6% | — | 10.6% | |
| LTM Jul 2026 | $151M | +115.7% | +25.2% | 0.4% | |
| LTM Mar 2026 | $35M | -66.0% | — | 2.6% | |
| LTM Mar 2026 | $8.89M | +5828.7% | — | 15.1% | |
| LTM Feb 2026 | $6.34M | -201.5% | +7.2% | 2.0% | |
| LTM Jun 2026 | $2.42M | -2.2% | +12.4% | 0.2% | |
| LTM Jun 2026 | $949K | -15.9% | — | 0.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding BSX) | $474.5K | -2.2% | +12.4% | 1.2% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
| Depreciation & Amortization | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
| Deferred Income Tax | (124M) | (63M) | (1M) | (70M) | (2M) |
| Stock-Based Compensation | 194M | 220M | 233M | 266M | 299M |
| Change in Working Capital | (351M) | (1.01B) | (770M) | (462M) | (246M) |
| Accounts Receivables | (279M) | (220M) | (238M) | (351M) | (269M) |
| Inventory | (346M) | (321M) | (660M) | (228M) | (188M) |
| Accounts Payables | 408M | (255M) | 118M | 243M | 296M |
| Other Working Capital | (134M) | (209M) | 10M | (126M) | (85M) |
| Other Non-Cash Items | 18M | 540M | 253M | 586M | 223M |
| Operating Cash Flow | 1.87B | 1.53B | 2.5B | 3.44B | 4.53B |
| Capital Expenditures | (554M) | (612M) | (800M) | (790M) | (876M) |
| Acquisitions (Net) | (1.43B) | (1.54B) | (1.81B) | (4.64B) | (1.59B) |
| Purchases of Investments | 96M | (24M) | 0 | 0 | 0 |
| Sales of Investments | 294M | 56M | 0 | 0 | 0 |
| Other Investing Activities | (1M) | 106M | (52M) | (257M) | (171M) |
| Investing Cash Flow | (1.6B) | (2.01B) | (2.57B) | (5.69B) | (2.64B) |
| Debt Repayment | 0 | (165M) | (4M) | 1.83B | (491M) |
| Common Stock Issued | 110M | 0 | 182M | 230M | 282M |
| Common Stock Repurchased | 0 | 136M | 0 | 0 | 0 |
| Dividends Paid | (55M) | (55M) | (28M) | 0 | 0 |
| Other Financing Activities | (150M) | (464M) | (145M) | (243M) | (186M) |
| Financing Cash Flow | (95M) | (548M) | 5M | 1.81B | (395M) |
| Effect of Forex Changes | (8M) | (9M) | (16M) | (11M) | 42M |
| Net Change in Cash | 171M | (1.04B) | (82M) | (449M) | 1.54B |
| Free Cash Flow | 1.32B | 914M | 1.7B | 2.65B | 3.66B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.